Texas Instruments 10-Qquarter ended 2026-09-30

Executive Summary

Texas Instruments sells analog and embedded-processing chips to equipment and device manufacturers, earning revenue from semiconductor sales. Its strategy centers on lower-cost, internally owned 300mm manufacturing that offers customers dependable supply and gives the company greater production control. Q3 revenue grew 28% as broad-based demand recovery, led by Analog, translated into substantially higher margins and earnings. The planned ≈$7.5B Silicon Labs acquisition adds a major strategic commitment alongside its manufacturing expansion. For investors, the opportunity is to turn recovering demand into durable profit and cash growth, while the threat is that another semiconductor downturn leaves expanded factories underused.

What's Happening in the Business

• Demand recovered across end markets and regions, with revenue increasing 11% sequentially. Management attributed the improvement to both the semiconductor cycle and increasing semiconductor content in customers’ products; this quarter alone cannot establish how much growth will persist beyond the recovery.
• Analog drove most of the revenue and profit increase, with Signal Chain leading growth across its two product lines. Embedded Processing also benefited from stronger demand, although management expects manufacturing costs to weigh more heavily on that business as its LFAB factory ramps.
• Manufacturing expansion continues despite lower capital spending. Management says 300mm production costs ≈40% less per chip than 200mm production, while owned factories support internal sourcing and supply-chain control. Expansion costs nevertheless partly offset year-to-date gross-profit growth.
• Silicon Labs: the cash acquisition is expected to close in H1 2027, subject to regulatory approval and customary conditions. Texas Instruments plans to use cash and debt, and has arranged a $5.0B acquisition-related delayed-draw facility.
• Inventory days fell to 194 from 222 as inventory declined modestly and sales recovered. This improves the relationship between stock and demand, but leaves substantial inventory to manage through the cycle.

Key Financial Highlights

• Operating leverage: Q3 operating margin reached 47.5% from 35.1%, with research, development and administrative expenses rising only modestly. The absence of the prior-year $85M restructuring charge also helped; the improvement was not entirely demand-driven.
• Government support: 9M CHIPS Act cash benefits totaled $1.48B, comprising $1.10B of incentive proceeds outside operating cash flow and $380M of tax-credit benefits included in it. The free-cash-flow calculation above excludes the separately received incentive proceeds.
• Capital returns and dilution: 9M dividends were $3.88B and repurchases were $233M, but shares outstanding increased from ≈907M to ≈914M; buybacks did not offset issuance. Employee stock-option exercises generated $770M. Management announced a 7% quarterly dividend increase to $1.52 per share.
• Acquisition funding capacity: cash and short-term investments increased to $8.14B, while debt principal declined to $13.7B after a $500M maturity repayment. The pending acquisition could reverse that debt reduction.

Risk Assessment

• Factory utilization and cyclicality: expanded internal capacity carries significant fixed costs, so another demand downturn could reverse margin gains, particularly while LFAB ramps and Embedded Processing absorbs manufacturing costs.
• Acquisition execution and financing: the ≈$7.5B Silicon Labs transaction requires approvals and cash-and-debt funding, while the arranged $5.0B facility has a 364-day term, creating financing-management needs if drawn.
• Inventory exposure: 194 days of inventory leaves Texas Instruments exposed to slower sell-through if the broad-based recovery weakens.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

What to Watch

• Analog recovery: Signal Chain currently leads growth; continued Analog expansion would support a durable recovery, while renewed contraction would suggest the rebound was mainly cyclical.
• Manufacturing economics: management expects 2026 capital expenditures of $2B–$3B; future filings should show whether 300mm expansion and LFAB ramp-up support sales and margins or leave costly underused capacity.
• Silicon Labs completion: management expects closing in H1 2027; approvals, final financing and subsequent acquired-business performance will distinguish successful expansion from delay, heavier borrowing or integration problems.
• Cash available to shareholders: current cash growth benefits from lower capital spending and government support; later filings should show whether operating cash flow sustains dividends and acquisition funding as those benefits change.

Not present in this filing: Item 3, Quantitative and Qualitative Disclosures About Market Risk.